Developing KNX100 to help with opioid withdrawal symptoms

Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.

NIH-funded research Kinoxis Therapeutics Pty LTD · NIH-11161503

This project is developing a new medication called KNX100 to help people manage the difficult symptoms of opioid withdrawal.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionKinoxis Therapeutics Pty LTD NIH-funded
Lab location1 site (Camberwell, Australia)
Project IDNIH-11161503 on NIH RePORTER

What this research studies

We are working on a new medication, KNX100, which has shown promise in animal models for reducing opioid withdrawal symptoms. This medication targets a specific system in the brain to help ease discomfort. Our next steps involve carefully testing KNX100 in people to make sure it is safe and well-tolerated. This initial testing is crucial to see if it can move forward to larger studies that will confirm its effectiveness.

Who could benefit from this research

Good fit: Patients who are experiencing or anticipate opioid withdrawal symptoms may be ideal candidates for future stages of this research.

Not a fit: Patients not experiencing opioid withdrawal symptoms would not directly benefit from this specific treatment.

Why it matters

Potential benefit: If successful, KNX100 could offer a new way to reduce the severe physical and emotional distress experienced during opioid withdrawal.

How similar studies have performed: KNX100 is a novel small molecule, and while preclinical studies have shown promise, its effectiveness in humans is currently untested.

Where this research is happening

Camberwell, Australia

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Breast Cancer
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.